West Pharmaceutical Services Stock Price, News & Analysis (NYSE:WST)

West Pharmaceutical Services trades on the New York Stock Exchange (NYSE) under the ticker symbol "WST."

West Pharmaceutical Services declared a quarterly dividend on Thursday, July 25th. Shareholders of record on Wednesday, October 23rd will be paid a dividend of $0.15 per share on Wednesday, November 6th. This represents a $0.60 annualized dividend and a dividend yield of 0.42%. The ex-dividend date of this dividend is Tuesday, October 22nd. View West Pharmaceutical Services' Dividend History.

West Pharmaceutical Services announced that its Board of Directors has authorized a stock repurchase program on Thursday, February 15th 2018, which allows the company to buyback 800,000 outstanding shares, according to EventVestor. This buyback authorization allows the company to purchase shares of its stock through open market purchases. Stock buyback programs are typically an indication that the company's board believes its shares are undervalued.

West Pharmaceutical Services Inc. (NYSE:WST) issued its quarterly earnings results on Thursday, July, 25th. The medical instruments supplier reported $0.89 earnings per share for the quarter, beating the consensus estimate of $0.72 by $0.17. The medical instruments supplier had revenue of $469.70 million for the quarter, compared to analyst estimates of $459.90 million. West Pharmaceutical Services had a net margin of 12.94% and a return on equity of 16.93%. The firm's quarterly revenue was up 5.0% compared to the same quarter last year. During the same period in the previous year, the company posted $0.70 EPS. View West Pharmaceutical Services' Earnings History.

West Pharmaceutical Services is scheduled to release their next quarterly earnings announcement on Thursday, October 24th 2019. View Earnings Estimates for West Pharmaceutical Services.

West Pharmaceutical Services issued an update on its FY19 earnings guidance on Thursday, July, 25th. The company provided earnings per share guidance of $3.00-3.10 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.89. The company issued revenue guidance of $1.810-1.825 billion, compared to the consensus revenue estimate of $1.81 billion.

3 brokers have issued 12-month price targets for West Pharmaceutical Services' stock. Their forecasts range from $112.16 to $122.00. On average, they anticipate West Pharmaceutical Services' stock price to reach $117.08 in the next year. This suggests that the stock has a possible downside of 18.2%. View Analyst Price Targets for West Pharmaceutical Services.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for West Pharmaceutical Services in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for West Pharmaceutical Services.

News stories about WST stock have trended negative on Friday, according to InfoTrie. The research firm rates the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. West Pharmaceutical Services earned a media sentiment score of -2.9 on InfoTrie's scale. They also assigned news stories about the medical instruments supplier a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for West Pharmaceutical Services.

West Pharmaceutical Services saw a increase in short interest in the month of August. As of August 15th, there was short interest totalling 600,600 shares, an increase of 24.6% from the July 15th total of 481,900 shares. Based on an average daily trading volume, of 292,900 shares, the short-interest ratio is currently 2.1 days. Currently, 0.8% of the shares of the stock are sold short. View West Pharmaceutical Services' Current Options Chain.

Some companies that are related to West Pharmaceutical Services include Humana (HUM), Siemens Healthineers (SHL), ESSILOR INTL S/S (ESLOY), Regeneron Pharmaceuticals (REGN), Actelion (ALIOF), Zimmer Biomet (ZBH), ASTELLAS PHARMA/ADR (ALPMY), Takeda Pharmaceutical (TKPYY), RESMED/IDR UNRESTR (RMD), FRESENIUS SE &/S (FSNUY), Takeda Pharmaceutical (TAK), McKesson (MCK), LONZA GRP AG/ADR (LZAGY), COLOPLAST A/S/ADR (CLPBY) and Alexion Pharmaceuticals (ALXN).

Based on aggregate information from My MarketBeat watchlists, some companies that other West Pharmaceutical Services investors own include Nike (NKE), NVIDIA (NVDA), Medtronic (MDT), Square (SQ), Stanley Black & Decker (SWK), Veeva Systems (VEEV), CVS Health (CVS), Honeywell International (HON), Johnson & Johnson (JNJ) and Walmart (WMT).

West Pharmaceutical Services' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Price T Rowe Associates Inc. MD (12.07%), Vanguard Group Inc. (9.93%), BlackRock Inc. (9.78%), BlackRock Inc. (9.78%), Bamco Inc. NY (2.16%) and JPMorgan Chase & Co. (2.10%). Company insiders that own West Pharmaceutical Services stock include Daniel Malone, Karen Flynn, Patrick J Zenner and William J Federici. View Institutional Ownership Trends for West Pharmaceutical Services.

WST stock was sold by a variety of institutional investors in the last quarter, including Ellis Investment Partners LLC, Renaissance Technologies LLC, First Trust Advisors LP, Schroder Investment Management Group, Janus Henderson Group PLC, Janus Henderson Group PLC, Royal Bank of Canada and Eagle Asset Management Inc.. View Insider Buying and Selling for West Pharmaceutical Services.

WST stock was acquired by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, Invesco Ltd., WCM Investment Management LLC, AMI Asset Management Corp, Price T Rowe Associates Inc. MD, Amundi Pioneer Asset Management Inc., AQR Capital Management LLC and BlackRock Inc.. View Insider Buying and Selling for West Pharmaceutical Services.

Shares of WST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of WST stock can currently be purchased for approximately $143.09.

West Pharmaceutical Services has a market capitalization of $10.55 billion and generates $1.72 billion in revenue each year. The medical instruments supplier earns $206.90 million in net income (profit) each year or $2.81 on an earnings per share basis. West Pharmaceutical Services employs 7,700 workers across the globe.View Additional Information About West Pharmaceutical Services.

The official website for West Pharmaceutical Services is http://www.westpharma.com/.

West Pharmaceutical Services' mailing address is 530 HERMAN O. WEST DRIVE, EXTON PA, 19341. The medical instruments supplier can be reached via phone at 610-594-2900 or via email at [email protected]